A drug discovery platform built on dual-binding antibodies with sensor domains that act as molecular switches: the attached therapeutic payload stays inactive until the antibody binds its target, and reverts to inactive on disengagement. Bonum's lead application is regulated cytokine therapeutics designed to drive anti-tumor immune responses in the tumor microenvironment.

• ·Sensor domains that gate therapeutic activity on target engagement
• ·Reversible regulation rather than irreversible protease-dependent activation
• ·Sensor domains engineerable against peptides, proteins, or metabolites
• ·Dual-binding antibody format combining targeting and safety control